Q32 Bio positive 36-week Phase 2a SIGNAL-AA topline results for bempikibart in severe alopecia
Q32 Bio reports positive 36-week Phase 2a SIGNAL-AA topline results for bempikibart in severe alopecia areata
- Part B of the SIGNAL-AA trial showed clinically meaningful efficacy for bempikibart in severe alopecia areata.
- Bempikibart demonstrated a well-tolerated safety profile through 36 weeks of treatment in the Phase 2a study.
- Q32 Bio plans to advance bempikibart into a registration-directed program in the first half of 2027.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.